SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, include area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|Item 5.07.|| |
Submission of Matters to a Vote of Security Holders.
On June 16, 2021, Galera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 21,474,218 shares of common stock were present online or represented by proxy at the meeting, representing approximately 85.0% percent of the Company’s outstanding common stock as of the April 23, 2021 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2021.
Item 1 — Election of two Class II Directors to serve until the 2024 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
|NOMINEE||Votes FOR||Votes WITHHELD||Broker Non-Votes|
Item 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021.
|Votes FOR||Votes AGAINST||Votes ABSTAINED||Broker Non-Votes|
Based on the foregoing votes, Lawrence Alleva and Kevin Lokay were elected as Class II Directors and Item 2 was approved.
|Item 8.01|| |
On June 16, 2021, the Company ceased enrolling subjects in its Phase 2 pilot trial of avasopasem in hospitalized patients who are critically ill with COVID-19. Enrollment in the trial was limited at the three centers that participated. Due to the success of the vaccines and the overall decline in COVID-related hospitalizations in the United States, the Company has determined that it is not feasible to complete the trial.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|GALERA THERAPEUTICS, INC.|
|Date: June 17, 2021||By:|
J. Mel Sorensen, M.D.
|President and Chief Executive Officer|